BACKGROUND: Growth differentiation factor 15 (GDF15), a stress-responsive cytokine produced in cardiovascular cells under conditions of inflammation and oxidative stress, is emerging as an important prognostic marker in individuals with and without existing cardiovascular disease (CVD). We therefore examined the clinical and genetic correlates of circulating GDF15 concentrations, which have not been investigated collectively.
lar events, and mortality in community-dwelling adults (9 -11 ) . Thus, GDF15 appears to be an important biomarker of cardiovascular disease (CVD) that confers prognostic information in addition to that of established risk factors and other biomarkers, including natriuretic peptides and C-reactive protein (CRP) (9, 11 ) .
Considering the emerging role of GDF15 as a prognostic biomarker, we sought to understand its genetic and clinical correlates. Although previous studies have highlighted the correlation of selected clinical factors with GDF15 expression, the contribution of genetic factors to interindividual variation in GDF15 concentrations has not been evaluated comprehensively. To examine genetic correlates, we estimated heritability in a familybased cohort and conducted a genomewide association study to explore the association of genetic loci with circulating GDF15 concentrations.
Materials and Methods

STUDY SAMPLES
The Framingham Heart Study (FHS) was initiated in 1948 to investigate risk factors for CVD. The children (and their spouses) of the original participants were enrolled in the Framingham Offspring Cohort in 1971 (12 ) . GDF15 concentrations were measured during a routine examination of the offspring cohort (1995) (1996) (1997) (1998) . Of the 3532 eligible participants, we excluded participants with missing biomarker measurements (n ϭ 82), heart failure (n ϭ 38), left ventricular (LV) systolic dysfunction as revealed by echocardiography (defined as LV fractional shortening Ͻ0.30 or mild or greater LV systolic dysfunction by visual inspection) (n ϭ 302), or missing covariates (n ϭ 60). We additionally excluded participants with previous myocardial infarction (n ϭ 59) from the clinical-correlates analyses, leaving 2991 participants for that analysis. All participants provided written informed consent, and the protocol was approved by the Institutional Review Board at Boston University Medical Center.
For the genetic analyses, we used additional data from 898 individuals enrolled in the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study, a community-based cohort of elderly individuals living in Sweden (see Data Methods in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol58/ issue11) (10 ) .
CLINICAL ASSESSMENT
All FHS participants underwent routine medical history review, physical examination, and laboratory testing, as described previously (12 ) . Participants regularly smoking cigarettes during the year before the baseline examination were considered current smokers. Diabetes mellitus was defined as a fasting glucose concentration Ն126 mg/dL (Ն7.0 mmol/L) or the use of insulin or oral hypoglycemic medications. The estimated glomerular filtration rate (eGFR) was calculated by means of the Modification of Diet in Renal Disease equation (13 ) . Metabolic syndrome was defined as described previously (14 ) .
LABORATORY TESTING
Blood samples were collected after an overnight fast and centrifuged immediately. Citrate-treated plasma samples were stored at Ϫ80°C. GDF15 concentrations in the FHS samples were measured with a precommercial, automated electrochemiluminescence immunoassay on a Cobas e 411 analyzer (Roche Diagnostics). The assay has a limit of detection Ͻ10 ng/L, a linear measurement interval up to 20 000 ng/L, and interassay imprecisions of 2.3% and 1.8% at GDF15 concentrations of 1100 ng/L and 17 200 ng/L, respectively. GDF15 values obtained with the electrochemiluminescence assay correlate closely with the values measured with a previously described immunoradiometric assay (r ϭ 0.980; slope, 1.049; y intercept, Ϫ136 ng/L; n ϭ 45 samples with GDF15 concentrations of 567-13 334 ng/L) (15 ) that was used to measure GDF15 concentration in the PIVUS samples (10 ) . The high-sensitivity assay for CRP and the assay for B-type natriuretic peptide (BNP) were performed as previously described (16 ) . Troponin I was measured with a high-sensitivity immunoassay (Erenna hsTnI; Singulex) (17 ) .
GENOMEWIDE GENOTYPING AND IMPUTATION
The genotyping of FHS samples was conducted with the Affymetrix 500K mapping array and the Affymetrix 50K gene-focused MIP (molecular inversion probe) array. Genotypes from the Affymetrix 500K mapping array were called with CHIAMO software. Imputation of genotypes to the HapMap set of 2.5 ϫ 10 6 singlenucleotide polymorphisms (SNPs) (CEU population, release 22, build 36; http://hapmap.ncbi.nlm.nih.gov/) was performed with MACH (version 1.0.15) (18 ) . Genomewide genotyping in the PIVUS population was performed with the HumanOmniExpress BeadChip (Illumina). Genotypes were called with GenCall software implemented in GenomeStudio. Imputation to the same HapMap reference panel was performed with IMPUTE version 2 (19 ) .
STATISTICAL ANALYSES
Healthy sample (FHS cohort).
To examine reference values, we studied a healthy subset of 1159 participants without any major medical conditions, including coronary heart disease, heart failure, atrial fibrillation, di-abetes, hypertension, obesity [body mass index (BMI) Ն30 kg/m 2 ], valvular heart disease (systolic murmur Ն3/6 in severity or any diastolic murmur), pulmonary disease (forced expiratory volume in 1 s below the lower reference limit), or serum creatinine Ն2.0 mg/dL (Ն1768 mol/L). Simple empirical estimates for the 2.5th, 10th, 50th, 90th, and 97.5th percentiles were examined by 10-year age and sex categories.
Clinical correlates (FHS cohort)
. GDF15 concentrations were log-transformed because of the right-skewed distribution of the data. To examine the association of GDF15 with clinical covariates, we used a forwardselection linear regression model, with a P value Ͻ0.05 chosen for entry. Age and sex were forced into the models; candidate covariates included systolic blood pressure, diabetes, BMI, cigarette smoking, total and HDL cholesterol, hypertension treatment, LV hypertrophy, atrial fibrillation, eGFR, and NSAID use. NSAID use was included because these drugs are known to induce GDF15 gene expression (20 ) .
In secondary analyses, the association of GDF15 concentration with the metabolic syndrome was examined in age-and sex-adjusted models. Cardiovascular risk factors were examined in aggregate with the Framingham CVD risk score (21 ) . Generalized estimating equations were used in secondary analyses to account for familial correlations.
Heritability (FHS cohort).
The heritability of GDF15 was estimated with variance component models that use Sequential Oligogenic Linkage Analysis Routines (22 ) . Heritability estimates were age-and sex-adjusted and multivariable-adjusted (age, sex, systolic blood pressure, antihypertensive medication use, diabetes mellitus, and smoking status).
Genomewide association study, replication, and metaanalysis (FHS and PIVUS cohorts).
The associations of genetic variants with GDF15 concentration in the FHS cohort were tested with an additive genetic model that uses linear mixed-effects models to accommodate pedigree data. We adjusted for age, sex, systolic blood pressure, antihypertensive medication use, diabetes mellitus, and smoking status. Results were considered significant genomewide at P values Ͻ5 ϫ 10 Ϫ8 . In secondary analyses, we tested the NSAID ϫ SNP interaction term for hits of genomewide significance within the FHS population.
We then performed a separate genomewide association study with the PIVUS cohort to replicate the FHS findings with an independent cohort and to metaanalyze the results. Owing to differences between the FHS and PIVUS populations in GDF15 distribution, we determined an inverse normal transformation to be the most appropriate for metaanalysis of the genetic data. Genomewide association analyses were performed with the PIVUS cohort by means of an additive model and linear regression, with adjustment for the same covariates as the FHS cohort analyses. PIVUS analyses were also adjusted for 2 principal components to adjust for population stratification. We used fixed effects with inverse variance weighting in the metaanalysis of the results for the 2 cohorts. Heterogeneity in allelic effects between the FHS and PIVUS cohorts were assessed by means of the Cochran Q statistic. Imputed results were filtered for a minor-allele frequency Ͻ0.01, and the imputed ratio or information score was examined for quality control. A ratio Ͼ0.4 was considered acceptable. The genomic control parameter was 1.05 in the FHS cohort, 1.01 in the PIVUS cohort, and 1.03 in the metaanalysis; therefore, analyses were not adjusted by genomic control to account for residual stratification within or between cohorts. We conducted conditional analyses by conditioning on each of the most significant SNPs for GDF15 in the FHS cohort (rs749451), the PIVUS cohort (rs1054564), and the metaanalysis (rs888663). We performed genomewide association analyses separately in each study: We accounted for each SNP alone and in 2-SNP combinations, and we metaanalyzed results to determine whether SNPs of genomewide significance represented independent signals. We also performed secondary analyses in which we adjusted for BMI (correlated with the GDF15 concentration in the PIVUS cohort but not in the FHS cohort) and adjusted metaanalysis results for 2 principal components to account for stratification within or between cohorts.
IN SILICO ASSOCIATION OF GENETIC VARIANTS AND CLINICAL
TRAITS
The association of 3 independent variants of genomewide significance (rs888663, rs749451, and rs1054564) with lipid traits was examined in a previously published genomewide association study of Ͼ100 000 individuals of European descent (23 ) . These GDF15 variants were searched against a collected database of expression SNPs to investigate any association with levels of cis gene expression across different tissue types (see Data Methods in the online Data Supplement).
Results
STUDY SAMPLE
Characteristics of the overall sample of 2991 FHS participants are summarized in Table 1 . The mean age was 59 years, and 56% of the participants were women. The median GDF15 concentration in the general FHS sample was 1020 ng/L (interquartile range, 803-1362 ng/L) in men and 1017 ng/L (interquartile range, 809 -1297 ng/L) in women.
The GDF15 concentration in the subset of apparently healthy individuals free of major medical comorbidities (n ϭ 1159; Table 2 ) varied with age but not by sex. The median GDF15 concentration was 901 ng/L. For men 30 -39 years of age, the median and 90th percentile GDF15 concentrations were 651 ng/L and 1197 ng/L, respectively, whereas the corresponding values for men 70 -79 years of age were 1389 ng/L and 2030 ng/L. Within the apparently healthy sample, 21% of the participants had a GDF15 concentration above the previously established upper reference limit of Ͼ1200 ng/L (15 ).
CLINICAL CORRELATES OF GDF15 IN THE FHS COHORT
In multivariable analyses, men and women had similar GDF15 concentrations. GDF15 concentration was positively associated with age, diabetes, antihypertensive treatment, smoking, and NSAID use but was negatively associated with total cholesterol, HDL cholesterol, and eGFR (Table 3 ). The R 2 value for this model was 0.38. In secondary analyses, the GDF15 concentration was significantly associated with the metabolic syndrome in age-and sex-adjusted analyses (P Ͻ 0.0001). GDF15 concentration increased across quartiles of the Framingham CVD score (Fig. 1A) and was positively correlated with the risk score in age-and sex-adjusted analyses (P Ͻ 0.0001).
Secondary analyses also showed that the positive association of NSAID use with GDF15 concentration appeared to be independent of inflammation, because the correlation persisted within the group of apparently healthy individuals (P ϭ 0.006), after exclusion of participants with inflammatory arthritis (P ϭ 0.01), and after adjustment for CRP (P ϭ 0.01). Secondary analyses that adjusted for relatedness within our sample with generalized estimating equation (GEE) models did not change the results appreciably. Inclusion of troponin I measured with a high-sensitivity assay (hsTnI), BNP, or CRP in the clinical-correlates analysis did not change our findings materially (see Table 1 in the online Data Supplement), although all 3 biomarkers were modestly correlated with GDF15 concentration [hsTnI, r ϭ 0.19 (P Ͻ 0.0001); BNP, r ϭ 0.29 (P Ͻ 0.0001); CRP, r ϭ 0.25 (P Ͻ 0.0001)].
GENETIC CORRELATES OF GDF15
The age-and sex-adjusted heritability of GDF15 in the FHS cohort was 0.38 (P ϭ 2.5 ϫ 10 Ϫ11 ), and the multivariable-adjusted heritability was 0.30 (P ϭ 4.8 ϫ 10 Ϫ8 ).
Nine SNPs had significant associations genomewide (P Ͻ 5 ϫ 10 Ϫ8 ) in the FHS cohort (Table 4 ; for details see Table 2 in the online Data Supplement). These SNPs were located in noncoding regions near the GDF15 and PGPEP1 (pyroglutamyl-peptidase I) genes (see Table 3 in the online Data Supplement for pairwise linkage disequilibrium data). The most significantly associated SNP (rs749451) had a P value of 1.9 ϫ 10 Ϫ31 and explained 2.5% of the residual phenotypic variance in GDF15 concentration. Three of these 9 SNPs (rs1054564, rs1227731, rs3195944) also had genome- wide associations with GDF15 in the PIVUS sample. Metaanalysis also revealed 8 SNPs near GDF15 with genomewide significance, with rs888663 being the most significantly associated SNP (P ϭ 2.7 ϫ 10 Ϫ32 ); Fig. 1B displays GDF15 concentrations according to rs888663 genotype. The regional-association plot in Fig. 2 demonstrates that all SNPs with genomewide significance were well within 100 kb of the GDF15 gene.
Secondary analyses that adjusted for the first 2 principal components did not substantively alter metaanalysis results (see Table 4 in the online Data Supplement), and adjustment for BMI did not change the results meaningfully. There was no statistically significant interaction between NSAID use or eGFR and the results for the loci with genomewide significance within the FHS sample (P Ͼ 0.05 for all). Adjustment for eGFR did not attenuate heritability estimates (h 2 ϭ Table 2 for estimated coefficients and SEs, Table 3 for pairwise linkage disequilibrium values between SNPs, Fig. 1 for a quantile-quantile plot, and Fig. 2 for a Manhattan plot of the genomewide association study. b Chr, chromosome; MAF, minor-allele frequency; UTR, untranslated region.
Fig. 2. Regional-association plot of metaanalysis loci associated with circulating GDF15 concentrations.
CEU, specific population within the HapMap database; cM/Mb, centimorgans per megabase.
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Conditional analyses accounting for rs888663, rs749451, and rs1054564 revealed 2 potentially independent signals: 1 signal from rs888663/rs749451 (r 2 ϭ 0.43 for the SNPs with each other), and 1 signal from rs1054564 (see Table 5 in the online Data Supplement). When conditioned on these 2 signals, no additional SNPs reached genomewide significance. Although the directionality of the association between SNP genotype and GDF15 concentration was consistent between studies, there was nominal evidence (P Ͻ 0.05, Cochran Q statistic) of heterogeneity in allelic effects between the FHS and PIVUS results, despite the similarity of the 2 populations in allele frequencies (see Table 2 in the online Data Supplement for allele frequencies; rs888663, P ϭ 0.04; rs749451, P ϭ 0.0005; rs1054564, P ϭ 0.001).
Putative functional variants. All 3 SNPs associated with GDF15 (rs888663, rs749451, and rs1054564) were associated with cis gene expression in lymphocyte, monocyte, and adipose tissue cell lines (24 -26 ) . Specifically, rs749451 and rs888663 were associated with PGPEP1 gene expression (P ϭ 1.32 ϫ 10 Ϫ11 and 4.86 ϫ 10 Ϫ4 , respectively). This gene encodes pyroglutamyl peptidase I and abuts GDF15 on chromosome 9p13.11. Both rs1054564 and rs888663 were associated with cis expression of the LRRC25 (leucine rich repeat containing 25) gene, which is also on 9p13.11 (P ϭ 3.61 ϫ 10 Ϫ66 and 7.81 ϫ 10 Ϫ7 , respectively). In addition, rs1054564 was associated with trans expression of the CRLF2 (cytokine receptor-like factor 2) gene, located on chromosome Xp22.3 (P ϭ 1.61 ϫ 10 Ϫ11 ), and the LRRC31 (leucine rich repeat containing 31) gene, which is on chromosome 3q26.2 (P ϭ 2.87 ϫ 10
Ϫ11
).
In silico association with clinical traits. Given the crosssectional association of GDF15 and both total cholesterol and HDL cholesterol, we pursued an in silico investigation of the 2 independent GDF15 variants within a published genomewide association study of lipid traits (23 ) . Our genomewide-significant GDF15 SNP rs1054564 was associated with HDL cholesterol (P ϭ 0.025). Specifically, the allele related to higher GDF15 concentrations was associated with lower HDL cholesterol, a finding consistent with the association found in the clinical correlates of GDF15.
Discussion
In this report, we describe the clinical and genetic correlates of GDF15 in the community. Our findings demonstrate that higher circulating GDF15 concentrations are associated with increasing cardiometabolic risk factors in individuals without overt CVD. Our findings also suggest that genetic factors play an important role in determining GDF15 concentrations. Additive genetic effects may explain up to 38% of the phenotypic variation in GDF15 concentration, which is comparable to the proportion of the variation explained by clinical factors. Our genomewide association studies showed that specific variants near the GDF15 gene on chromosome 19p13.11 were strongly associated with GDF15 concentration. Furthermore, GDF15 variants were associated with gene expression in published databases.
Experimental studies have shown that the GDF15 gene is expressed in human atherosclerotic plaque (27 ) and cardiac myocytes after an ischemic insult (28 ) . Under these conditions, GDF15 appears to provide protection against cardiac injury via antiinflammatory (29 ) , antiapoptotic (28 ), and antihypertrophic (30 ) pathways. Clinical studies of individuals with existing CVD (2-8 ) and of community-based populations (9 -11 ) have largely shown higher GDF15 concentrations to be associated with adverse outcomes, although whether GDF15 is a mediator or a marker of CVD remains unclear. It may be that GDF15 is similar to the natriuretic peptides, which have protective biological effects but are increased in individuals at risk for CVD, presumably reflecting a response to increased hemodynamic stress (31 ) . Accordingly, understanding the clinical and genetic correlates of GDF15 may elucidate pathways underlying the association of GDF15 with CVD.
As in previous studies (15 ) , GDF15 concentration and age showed a strong association, which was quite pronounced even in apparently healthy adults. Using the previously studied upper reference limit of 1200 ng/L (15 ), we found that Ͻ10% of adults 40 -49 years of age met the criteria for "abnormal" GDF15 concentrations. In contrast, Ͼ50% of apparently healthy adults 70 -79 years of age were classified as having an increased GDF15 concentration when the same cutoff was used. This marked increase in GDF15 concentration with age may be related to a higher burden of subclinical CVD, even within an ostensibly healthy population. GDF15 concentrations also have been shown to be increased in a number of advanced cancers (32 ) , but it is less likely that occult malignancies could be related to the age-related increase in GDF15 concentration. Lastly, owing to enhanced production upon kidney injury or disease, age-related renal dysfunction may lead to higher GDF15 concentrations, although age was a correlate even after we adjusted for eGFR in our study. In considering the potential clinical utility of GDF15 as a biomarker, it will be important to account for the robust association between age and GDF15 concentra-tion, an effect greater than any other clinical trait in apparently healthy adults.
We found no difference between the sexes in GDF15 concentration, in contrast to prior studies that examined individuals with acute coronary syndromes (3, 5, 6, (33) (34) (35) , heart failure (8 ), or older age (9, 10 ) -all of which demonstrated higher GDF15 concentrations in men than in women. It is possible that sex differences in CVD severity or subtype may have contributed to the previously observed differences in GDF15 concentrations.
We observed a strong association between higher GDF15 concentrations and cardiometabolic risk factors, including diabetes, hypertension, smoking, and low HDL, which precede the onset of overt CVD. Our findings are similar to those for older participants in the PIVUS study (10 ) , as well as those in the Rancho Bernardo Study (9 ) . Although the mechanisms by which GDF15 may modulate risk are not well understood, recent animal and clinical studies have shown that GDF15 is produced in adipocytes and may act as an adipokine (36 ) . Circulating GDF15 has been associated with insulin resistance in obese individuals (37 ) . Interestingly, higher GDF15 concentrations were associated with lower total cholesterol and LDL cholesterol in the community, as others have found (9, 10 ) . Experimental data suggest that oxidized LDL can induce GDF15 in atherosclerotic lesions (27 ) , and different LDL subtypes might be differentially associated with GDF15.
Lastly, we have shown that NSAID use is associated with higher circulating GDF15 concentrations, an association that has not previously been described. GDF15 is also known as an NSAID-activated gene, and experimental studies have shown NSAIDs to induce its expression, a process that appears to be independent of cyclo-oxygenase or prostanoids (20 ) . Inflammatory conditions such as rheumatoid arthritis have been associated with GDF15 increases (38 ) , but the association of NSAID use with GDF15 concentration persisted even after we excluded individuals with rheumatoid arthritis and adjusted for CRP as a marker of inflammation.
Our study is the first to report the heritability of GDF15 and suggests that circulating GDF15 concentrations are in part genetically determined. We conducted a metaanalysis of 2 community-based cohorts and found 8 SNPs in the region of the GDF15 gene that are associated with circulating concentrations on a genomewide-significant basis. Two of these SNPs appear to be independent signals, according to our conditional analyses. A missense variant in the promoter region in pairwise linkage disequilibrium with one of our loci with genomewide significance (rs4808793 and rs1054564, respectively; r 2 ϭ 0.40) has previously been associated with increased transcriptional activity and higher circulating GDF15 concentrations, as well as with favorable echocardiographic traits in hypertensive Chinese individuals (39 ) . Two of the SNPs with genomewide significance in our analysis (rs888663 and rs1054564) were previously associated with GDF15 concentration in a cohort of prostate cancer patients (40 ) , a result that also lends support to our findings.
Although we have shown that genetic factors play an important role in circulating GDF15 concentrations, the exact mechanism by which the 2 potentially independent signals modulate GDF15 expression remains unknown. We observed nominal evidence of heterogeneity between the 2 studies in the effect of genetic variants, which could potentially be attributed to clinical differences in age and cardiovascular risk factors. Alternatively, this pattern of heterogeneity in allelic effects and independent association signals could reflect differences between the 2 populations with respect to underlying and unobserved rare causal variants. Further studies are needed to explore factors that might explain this heterogeneity. Interestingly, 3 GDF15 variants with genomewide significance were strongly associated with cis gene expression of PGPEP1 and LRRC25, genes within 100 kb of GDF15. There is no known relationship between PGPEP1, LRRC25, and GDF15. Because these genetic variants are intergenic, they might upregulate expression via a promoter or other distal elements that may affect GDF15 expression itself.
One notable finding was that the C allele of one of the GDF15 loci (rs1054561) was associated with both higher GDF15 concentrations and lower HDL cholesterol concentrations. It is possible that genetically increased GDF15 concentrations could lead to lower HDL, but further prospective studies are needed to explore this association.
Several limitations of our study deserve mention. GDF15 concentrations in our sample of healthy participants were slightly higher than those reported by Kempf and colleagues, who studied a sample of elderly Swedish individuals. Several aspects of the Framingham cohort support the generalizability of our findings, including the community-based design and the rigorous characterization of participants who have been followed since the early 1970s. We cannot exclude the possibility that laboratory variation, unmeasured differences in the study cohorts, and/or undetected disease contributed to differences in the study findings. The cross-sectional nature of our study limits inferences of causality with respect to clinical correlates; thus, GDF15 may both contribute to and be a marker of cardiometabolic risk. Future studies involving larger sample sizes may be able to identify genetic variants outside of the GDF15 locus that might play an important role in determining GDF15 concentrations. Lastly, our sample consisted of white participants of European ancestry, limiting the generalizability of our findings to other racial and ethnic groups.
In summary, we have demonstrated that GDF15 is associated with cardiometabolic risk factors and that genetic factors play an important role in determining GDF15 concentrations. Importantly, using 2 community-based cohorts, we identified genetic variants in the region of the GDF15 gene on chromosome 19p13.11 that influence circulating GDF15 concentrations. Two variants were associated with altered gene expression in different blood cell lines, and one was associated with lower HDL concentrations. Further studies are required to elucidate how genetic factors regulate GDF15 expression and how these mechanisms relate ultimately to the development of CVD.
